Faeth Therapeutics (FTH) Change in Acquisitions & Divestments (2021 - 2026)

Faeth Therapeutics (FTH) has 6 years of Change in Acquisitions & Divestments data on file, last reported at $6.0 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 55.56% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.2 million (down 45.79% YoY) and the FY2025 annual result came in at $44.7 million, down 33.47% from the prior year.
• Change in Acquisitions & Divestments slipped to $6.0 million in Q1 2026, from $8.6 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $83.5 million in Q3 2022 to a low of -$83.5 million in Q4 2022.
• A 5-year average of $10.9 million and a median of $12.3 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments slumped 2132.05% — and 2023, when it surged 531.02%.
• Tracing FTH's Change in Acquisitions & Divestments over 5 years: stood at -$83.5 million in 2022, then soared by 113.02% to $10.9 million in 2023, then soared by 34.39% to $14.6 million in 2024, then tumbled by 41.14% to $8.6 million in 2025, then tumbled by 30.26% to $6.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $6.0 million (Q1 2026), $8.6 million (Q4 2025), and $11.6 million (Q3 2025), per Business Quant data.